Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Lower daily tenofovir dose of 150mg safe and effective in people with moderate renal impairment

A reduced tenofovir (Viread) dose of 150mg daily appears to be a safe and effective treatment for people with HIV who have moderate renal impairment, investigators from

Published
22 May 2015
By
Michael Carter
Is Gilead Sciences Its Own Worst Enemy?

Gilead's science is so good that it's actually destroying the company's business. Pharma companies, like most other businesses, make the bulk of their money through repeat business. Gilead, however, is doing something really no other drugmaker is doing -- namely curing patients of devastating infectious diseases.

Published
20 May 2015
From
Motley Fool
HIV immunity: rare gene differences offer hope for treatment

Seven years after the ‘Berlin patient’ was cured of HIV, scientists are looking to natural immunity through genetic variation to create vaccine and gene therapies

Published
12 May 2015
From
The Guardian
GSK team up with US researchers to advance search for HIV cure

Pharmaceutical giant GlaxoSmithKline have partnered with researchers from UNC-Chapel Hill to create a research center that will focus on finding a cure for HIV.

Published
12 May 2015
From
HIV / AIDS News From Medical News Today
Modern NNRTI regimens can be effective with 85% adherence

Some modern HIV treatment regimens can achieve viral suppression with adherence rates as low as 85%, investigators from the US Veteran Aging Cohort Study report in the

Published
12 May 2015
By
Michael Carter
Five antiretroviral combinations associated with increased risk of a cardiovascular event

Treatment with four individual and five combinations of anti-HIV drugs is associated with an increased risk of a cardiovascular event, investigators from the United States report in the

Published
08 May 2015
By
Michael Carter
US guidelines shift to integrase-based combinations for first-line treatment: Atripla relegated due to side effects

The rationale for dropping Atripla is due to concerns about the tolerability of efavirenz, especially the high rate of central nervous system related toxicities. Although this has been a long-standing community concern, DHHS guidelines have consistently recommended efavirenz in previous editions. This tolerability statement is made in the year that efavirenz comes off patent.

Published
06 May 2015
From
i-Base
HIV infection and low CD4 count associated with hardening of arteries

HIV infection is associated with an increased risk of hardening of the arteries, investigators report in the online edition of Clinical Infectious Diseases. The US study compared changes

Published
06 May 2015
By
Michael Carter
Researchers “un-can” the HIV virus

If the human immunodeficiency virus (HIV) is a bit like a hermetically sealed tin can no one has yet been able to break open, the good news is that researchers at the CHUM Research Centre, affiliated with the University of Montreal, have identified a way to use a “can opener” to force the virus to open up and to expose its vulnerable parts, allowing the immune system cells to then kill the infected cells.

Published
05 May 2015
From
Univesity of Montreal
People who don’t tell anyone else their HIV status have as good health outcomes as other people living with HIV

A large survey of people attending HIV clinics in the UK has found that those individuals who chose not to disclose their HIV status to other people

Published
01 May 2015
By
Roger Pebody
← First12345...386Next →

Filter by country